Airway Therapeutics closes $50M equity round
Analysis based on 7 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026
The $50 million equity round strengthens Airway Therapeutics' balance sheet, enabling it to advance its lead candidate through late-stage clinical development without immediate liquidity concerns. This financing signals investor confidence in the company's pipeline and may positively influence its valuation in future funding rounds.
Airway Therapeutics, a late-stage clinical biopharmaceutical company, announced the closing of a $50 million equity round to support the continued development of zelpultide alfa, its novel recombinant human surfactant protein D (rhSP-D) for the prevention of bronchopulmonary dysplasia (BPD) in very preterm infants. The round consists of $26 million previously raised through a SAFE financing and $24 million through a Series E-2 round. Approximately 94% of existing investors participated, including Cincinnati Children's and a syndicate of large family offices. Proceeds will fund the ongoing Phase 2b/3 clinical trial, CMC and analytical activities, and BLA readiness. The interim analysis completing the Phase 2b portion is expected by the end of Q2 2027.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard